Showing 3751-3760 of 5956 results for "".
- PulseSight: New Peer-Reviewed Data Highlighting Transferrin’s Therapeutic Potential for Dry AMDhttps://modernod.com/news/pulsesight-new-peer-reviewed-data-highlighting-transferrins-therapeutic-potential-for-dry-amd/2484176/PulseSight Therapeutics welcomed the publication of new scientific data reinforcing the therapeutic promise of transferrin (Tf) for the treatment of dry age-related macular degeneration (AMD). The study, conducted by
- Celltrion Receives FDA Approval for Eylea Biosimilar Eydenzelthttps://modernod.com/news/celltrion-receives-fda-approval-for-eylea-biosimilar-eydenzelt/2484171/The FDA has approved Celltrion's Eydenzelt (aflibercept-boav), a biosimilar referencing Eylea (aflibercept), for the treatment of wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO)
- Konan Medical Receives CE Marking for ObjectiveFIELD Analyzer (OFA)https://modernod.com/news/konan-medical-receives-ce-marking-for-objectivefield-analyzer-ofa/2484170/Konan Medical USA announced that its objectiveFIELD Analyzer (OFA) has received CE Marking under the European Medical Device Regulation (MDR). The CE Mark enables Konan Medical to offer its next-generation perimetry solution to healthcare providers throug
- AviadoBio and UgeneX Therapeutics Announce Agreement to Advance Gene Therapy for Retinitis Pigmentosahttps://modernod.com/news/aviadobio-and-ugenex-therapeutics-announce-agreement-to-advance-gene-therapy-for-retinitis-pigmentosa/2484165/AviadoBio and UgeneX Therapeutics announced an exclusive option and license agreement for the development and commercialization of UGX-202, an investigational AAV-based gene therapy currently in clinical development for retinitis pigmentosa (RP). The agreement
- Horizon Surgical Systems Announces World’s First Robotic Cataract Surgery Using the Polaris Platformhttps://modernod.com/news/horizon-surgical-systems-announces-worlds-first-robotic-cataract-surgery-using-the-polaris-platform/2484160/Horizon Surgical Systems announced the completion of the world’s first cataract surgery performed using its Polaris robotic platform. The milestone procedure was conducted by Uday Devgan, MD, FACS.
- Regenxbio Completes Enrollment in ATMOSPHERE and ASCENT Trials of Sura-Vec Gene Therapy for Wet AMDhttps://modernod.com/news/regenxbio-completes-enrollment-in-atmosphere-and-ascent-trials-of-sura-vec-gene-therapy-for-wet-amd/2484155/Regenxbio announced the completion of enrollment in its two pivotal phase 3 studies—ATMOSPHERE and ASCENT—evaluating surabgene lomparvovec (sura-vec, ABBV-RGX-314), an investigational one-time gene therapy for wet age-related macular degeneration (
- Virtual Field Launches DICOM 360 Sync Connectivity Hubhttps://modernod.com/news/virtual-field-launches-dicom-360-sync-connectivity-hub/2484151/Virtual Field announced the launch of DICOM 360 Sync, a connectivity hub that aims to redefine how practices connect diagnostics with medical records. DICOM 360 Sync is designed to deliver instant, autom
- Cirrus Therapeutics Raises $11 Million to Advance First-in-Class Ocular Gene Therapy Targeting Dry AMDhttps://modernod.com/news/cirrus-therapeutics-raises-11-million-to-advance-first-in-class-ocular-gene-therapy-targeting-dry-amd/2484149/Cirrus Therapeutics announced the close of an $11 million seed financing round to advance its gene and cell therapy pipeline. The company will use the funds to progress its lead program into IND-enabling studies.
- Kalaris Therapeutics Launches Phase 1b/2 Dose-Finding Trial of TH103 for Wet AMDhttps://modernod.com/news/kalaris-therapeutics-launches-phase-1b2-dose-finding-trial-of-th103-for-wet-amd/2484144/Kalaris Therapeutics has initiated patient enrollment in a phase 1b/2 multiple ascending dose (MAD) clinical study of TH103, its investigational therapy for wet age-related macular degeneration (AMD). The phase 1b/2 t
- The Vision Council Releases Focused inSights 2025: Smart Eyewearhttps://modernod.com/news/the-vision-council-releases-focused-insights-2025-smart-eyewear/2484143/The Vision Council announced the release of 'Focused inSights 2025: Smart Eyewear,' a consumer research report that highlights growing interest and evolving attitudes toward the developing smart eyewear category. Drawing on survey responses from more than 4